Overview Dividends

(BIO) Bio-Rad Laboratories - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0905722072

Instruments, Reagents, Test Kits,

BIO EPS (Earnings per Share)

EPS Growth (3Y CAGR): -12.96%
EPS Trend (3Y Correlation): -55.8%

BIO Revenue

Revenue Growth (3Y CAGR): -3.99%
Revenue Trend (3Y Correlation): -54.3%

Description: BIO Bio-Rad Laboratories November 05, 2025

Bio-Rad Laboratories (NYSE:BIO) is a global supplier of life-science research and clinical-diagnostic products, operating through two segments: Life Science and Clinical Diagnostics. The firm designs, manufactures, and markets instruments, reagents, consumables, and software that enable the separation, purification, characterization, and quantitation of biological materials for applications ranging from biopharma manufacturing to food safety and academic research.

Key metrics that illustrate Bio-Rad’s recent performance include FY 2023 revenue of roughly $3.1 billion (≈ 9 % year-over-year growth) and an operating margin near 18 %, supported by a steady R&D spend of about 12 % of sales. The company benefits from macro-level drivers such as rising global biotech R&D expenditures (projected CAGR ≈ 7 % through 2028) and expanding demand for molecular diagnostics driven by an aging population and increased screening for infectious diseases.

If you’re looking for a deeper quantitative analysis and forward-looking valuation, ValueRay’s platform offers a structured framework that can help you assess Bio-Rad’s risk-adjusted upside.

BIO Stock Overview

Market Cap in USD	8,612m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	1966-01-01

BIO Stock Ratings

Growth Rating	-47.5%
Fundamental	32.3%
Dividend Rating	-
Return 12m vs S&P 500	-30.4%
Analyst Rating	4.0 of 5

BIO Dividends

Currently no dividends paid

BIO Growth Ratios

Growth Correlation 3m	68.7%
Growth Correlation 12m	-33.1%
Growth Correlation 5y	-91.6%
CAGR 5y	-8.49%
CAGR/Max DD 3y (Calmar Ratio)	-0.15
CAGR/Mean DD 3y (Pain Ratio)	-0.26
Sharpe Ratio 12m	-0.30
Alpha	-35.46
Beta	0.969
Volatility	38.62%
Current Volume	179.6k
Average Volume 20d	220.2k
Stop Loss	291.9 (-5.8%)
Signal	0.26

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-675.9m TTM) > 0 and > 6% of Revenue (6% = 153.4m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 1.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 98.07% (prev 99.13%; Δ -1.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 491.5m > Net Income -675.9m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 5.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (26.9m) change vs 12m ago -3.79% (target <= -2.0% for YES)

Gross Margin 52.26% (prev 54.41%; Δ -2.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 25.62% (prev 24.33%; Δ 1.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -16.17 (EBITDA TTM -621.3m / Interest Expense TTM 49.1m) >= 6 (WARN >= 3)

Altman Z'' 6.40

(A) 0.27 = (Total Current Assets 3.03b - Total Current Liabilities 522.3m) / Total Assets 9.36b

(B) 0.80 = Retained Earnings (Balance) 7.46b / Total Assets 9.36b

(D) 2.46 = Book Value of Equity 7.29b / Total Liabilities 2.96b

Total Rating: 6.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.29

1. Piotroski 3.0pt = -2.0

2. FCF Yield 4.05% = 2.02

3. FCF Margin 13.17% = 3.29

4. Debt/Equity 0.03 = 2.50

5. Debt/Ebitda -0.31 = -2.50

6. ROIC - WACC (= -21.53)% = -12.50

7. RoE -9.97% = -1.66

8. Rev. Trend -54.31% = -4.07

9. EPS Trend -55.78% = -2.79

What is the price of BIO shares?

As of November 06, 2025, the stock is trading at USD 310.01 with a total of 179,617 shares traded.
Over the past week, the price has changed by -2.96%, over one month by +0.27%, over three months by +13.90% and over the past year by -17.17%.

Is Bio-Rad Laboratories a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Bio-Rad Laboratories (NYSE:BIO) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 32.29 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BIO is around 276.17 USD . This means that BIO is currently overvalued and has a potential downside of -10.92%.

Is BIO a buy, sell or hold?

Bio-Rad Laboratories has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BIO.

Strong Buy: 2
Buy: 2
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BIO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	333	7.4%
Analysts Target Price	333	7.4%
ValueRay Target Price	310.8	0.3%

BIO Fundamental Data Overview November 02, 2025

Market Cap USD = 8.61b (8.61b USD * 1.0 USD.USD)
P/E Forward = 32.7869
P/S = 3.3674
P/B = 1.117
P/EG = 1.1905
Beta = 0.969
Revenue TTM = 2.56b USD
EBIT TTM = -793.5m USD
EBITDA TTM = -621.3m USD
Long Term Debt = 1.20b USD (from longTermDebt, last fiscal year)
Short Term Debt = 38.1m USD (from shortTermDebt, last quarter)
Debt = 193.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 193.9m USD (from netDebt column, last quarter)
Enterprise Value = 8.32b USD (8.61b + Debt 193.9m - CCE 488.1m)
Interest Coverage Ratio = -16.17 (Ebit TTM -793.5m / Interest Expense TTM 49.1m)
FCF Yield = 4.05% (FCF TTM 336.7m / Enterprise Value 8.32b)
FCF Margin = 13.17% (FCF TTM 336.7m / Revenue TTM 2.56b)
Net Margin = -26.43% (Net Income TTM -675.9m / Revenue TTM 2.56b)
Gross Margin = 52.26% ((Revenue TTM 2.56b - Cost of Revenue TTM 1.22b) / Revenue TTM)
Gross Margin QoQ = 52.59% (prev 52.99%)
Tobins Q-Ratio = 0.89 (Enterprise Value 8.32b / Total Assets 9.36b)
Interest Expense / Debt = 6.34% (Interest Expense 12.3m / Debt 193.9m)
Taxrate = -20.69% (negative due to tax credits) (89.2m / -431.1m)
NOPAT = -957.7m (EBIT -793.5m * (1 - -20.69%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 5.80 (Total Current Assets 3.03b / Total Current Liabilities 522.3m)
Debt / Equity = 0.03 (Debt 193.9m / totalStockholderEquity, last quarter 6.74b)
Debt / EBITDA = -0.31 (negative EBITDA) (Net Debt 193.9m / EBITDA -621.3m)
Debt / FCF = 0.58 (Net Debt 193.9m / FCF TTM 336.7m)
Total Stockholder Equity = 6.78b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.22% (Net Income -675.9m / Total Assets 9.36b)
RoE = -9.97% (Net Income TTM -675.9m / Total Stockholder Equity 6.78b)
RoCE = -9.94% (EBIT -793.5m / Capital Employed (Equity 6.78b + L.T.Debt 1.20b))
RoIC = -11.98% (negative operating profit) (NOPAT -957.7m / Invested Capital 7.99b)
WACC = 9.55% (E(8.61b)/V(8.81b) * Re(9.59%) + D(193.9m)/V(8.81b) * Rd(6.34%) * (1-Tc(-0.21)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.34%
[DCF Debug] Terminal Value 76.58% ; FCFE base≈291.6m ; Y1≈359.7m ; Y5≈613.6m
Fair Price DCF = 361.7 (DCF Value 7.92b / Shares Outstanding 21.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -55.78 | EPS CAGR: -12.96% | SUE: 0.61 | # QB: 0
Revenue Correlation: -54.31 | Revenue CAGR: -3.99% | SUE: 0.06 | # QB: 0

Additional Sources for BIO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle